Key Products And Themes: 3Q Pharma Results Previewed
This article was originally published in Scrip
Executive Summary
Earnings season is upon us. Key motifs that will recur in pharma company briefings will include recent rhetoric on drug pricing (with pharma executive likely to emphasize how they are offering real value with innovative therapies); the threat – or for many, such as Amgen, Pfizer or Boehringer Ingelheim, the opportunity – of biosimilars given that a slew of blockbuster monoclonal antibodies are reaching or nearing loss of exclusivity; and the negative impact of currency trends on US dollar-reporting firms' sales and earnings. The perennial favorite of analyst question time, M&A intentions, will surely rear its head more than once, too.
You may also be interested in...
European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Drug Manufacturers Beg US FDA To Inspect Facilities, But Still Find Difficulties
As agency implements testing contract for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.
Need a specific report? 1000+ reports available
Buy Reports